Get the Stockscreener App
4.9484
0.17%
0.0084
Dogwood Therapeutics Inc stock is traded at $4.9484, with a volume of 6,028.
It is up +0.17% in the last 24 hours and up +5.51% over the past month.
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$4.94
Open:
$5.07
24h Volume:
6,028
Relative Volume:
0.16
Market Cap:
$9.46M
Revenue:
-
Net Income/Loss:
$-5.73M
P/E Ratio:
-0.7555
EPS:
-6.55
Net Cash Flow:
$-4.13M
1W Performance:
+0.37%
1M Performance:
+5.51%
6M Performance:
-7.68%
1Y Performance:
+0.00%
1-Day Range:
$4.94
$5.19
1-Week Range:
$4.65
$5.44
52-Week Range:
$1.62
$29.28
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
4.9484 | 10.13M | 0 | -5.73M | -4.13M | -6.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Is it too late to sell Dogwood Therapeutics Inc.2025 Market Trends & Low Drawdown Investment Ideas - Newser
Dogwood Therapeutics Inc. stock daily chart insightsJuly 2025 Momentum & Free High Return Stock Watch Alerts - Newser
What MACD and RSI say about Dogwood Therapeutics Inc.July 2025 Big Picture & Growth-Oriented Investment Plans - Newser
Dogwood Therapeutics Inc. stock trend outlook and recovery pathPortfolio Value Summary & Low Volatility Stock Suggestions - Newser
Visual analytics tools that track Dogwood Therapeutics Inc. performanceDip Buying & Long-Term Safe Investment Ideas - Newser
Can swing trading help recover from Dogwood Therapeutics Inc. lossesJuly 2025 Macro Moves & High Conviction Buy Zone Alerts - Newser
News impact scoring models applied to Dogwood Therapeutics Inc.Weekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser
Published on: 2025-08-19 07:09:46 - Newser
Does Dogwood Therapeutics Inc. show high probability of reboundWeekly Trend Summary & High Accuracy Trade Signal Alerts - Newser
Applying chart zones and confluence areas to Dogwood Therapeutics Inc.Quarterly Market Summary & Weekly Stock Breakout Alerts - Newser
Buy Rating for Dogwood Therapeutics: Promising Phase 2b Study Results and Strategic Financial Positioning - TipRanks
Leading vs lagging indicators on Dogwood Therapeutics Inc. performanceJuly 2025 Short Interest & Growth Focused Investment Plans - Newser
Real time breakdown of Dogwood Therapeutics Inc. stock performanceRisk Management & Long Hold Capital Preservation Tips - Newser
Can volume confirm reversal in Dogwood Therapeutics Inc.July 2025 Volume & Expert Approved Momentum Ideas - Newser
Exit strategy if you’re trapped in Dogwood Therapeutics Inc.July 2025 Review & Entry Point Confirmation Alerts - Newser
Sentiment analysis tools applied to Dogwood Therapeutics Inc.Market Volume Report & Real-Time Chart Breakout Alerts - Newser
Can Dogwood Therapeutics Inc. disrupt its industryJuly 2025 Action & Consistent Profit Trading Strategies - thegnnews.com
Applying Wyckoff theory to Dogwood Therapeutics Inc. stockLong Setup & Weekly High Return Stock Opportunities - Newser
Dogwood Therapeutics Inc.’s volatility index tracking explainedWeekly Market Report & Weekly High Momentum Picks - Newser
What are the analyst revisions for KMDAIs Dogwood Therapeutics Inc. stock a good investment in YEARJuly 2025 Technicals & Growth Focused Stock Pick Reports - 선데이타임즈
Dogwood Therapeutics Inc. Stock Fails to Break Resistance Traders ReactWeekly Earnings Recap & Comprehensive Market Scan Insights - beatles.ru
Dogwood Therapeutics Inc. Sees Relief Buying After Extended DropJuly 2025 Movers & Daily Growth Stock Tips - classian.co.kr
How to integrate Dogwood Therapeutics Inc. into portfolio analysis toolsTrade Volume Summary & Growth Focused Investment Plans - Newser
What does recent volatility data suggest for Dogwood Therapeutics Inc.2025 Technical Patterns & Smart Investment Allocation Insights - Newser
Chart based analysis of Dogwood Therapeutics Inc. trends2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Top Risks to Consider Before Buying Dogwood Therapeutics Inc. StockJuly 2025 Sentiment & Free Reliable Trade Execution Plans - Newser
Using AI based signals to follow Dogwood Therapeutics Inc.2025 Dividend Review & Accurate Buy Signal Alerts - Newser
Published on: 2025-08-15 16:18:19 - Newser
Chart Patterns Forming a Bullish Setup in Dogwood Therapeutics Inc.July 2025 Movers & Low Risk Profit Maximizing Plans - classian.co.kr
Dogwood Therapeutics, Inc. SEC 10-Q Report - TradingView
Dogwood Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Dogwood Therapeutics reports second quarter 2025 financial results - MarketScreener
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewswire
Dogwood's Non-Opioid Pain Drug Advances With Strong Safety Data in Phase 2b Cancer Trial - Stock Titan
Is Dogwood Therapeutics Inc. meeting your algorithmic filter criteriaQuarterly Profit Review & Target Return Focused Stock Picks - Newser
What makes Dogwood Therapeutics Inc. stock price move sharplyTrade Entry Summary & Verified Short-Term Plans - Newser
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):